Asset Class
Equities Research Hub
Global equity markets are currently navigating a 'risk-off' environment characterized by a significant rotation from technology to defensive sectors. This shift is highlighted by a sharp 5.9% decline in the US Momentum factor and a correction in US tech stocks, even as companies like Alphabet continue massive investments in AI infrastructure. Earnings reports for 4Q25 reveal a mixed landscape; while consumer names like Yum! Brands show resilience, sector-specific pressures such as multiple compression for Ferrari and disappointing guidance from Information Services firm Gartner have led to price target downward revisions. In Europe, pharmaceutical giants GSK and Novartis have issued guidance trailing consensus, further contributing to a cautious outlook in the region. Regional equity sentiment is also being shaped by political developments, most notably in Japan, where a projected LDP victory is expected to support 'Abenomics'-style stimulus alongside Bank of Japan rate hikes totaling 75bp. Additionally, the cooling of Brent crude prices toward $68/b amid diplomatic progress in the Middle East and large-scale renewable energy investments, such as Saudi Arabia's $2bn solar agreement with Turkey, are influencing broader market dynamics. Despite localized volatility and currency fluctuations, global PMIs suggest an underlying 2.8% annualized rise in GDP, providing a macro cushion for diversified equity portfolios.
2984 reports available
All reports
Page 19 of 125
Research Morning Line Express
Natsos · Jun 9, 2026
Apple Inc. WWDC 2026: Setting The Stage For The Agentic Smartphone Era
Bank of America · Jun 9, 2026
On The Road With Goldman Sachs Asia Pacific Taiwan Computex Tour And Corporate Day
Goldman Sachs · Jun 9, 2026
Tandem Diabetes Care Inc. Key Takeaways
Goldman Sachs · Jun 9, 2026
Europe Media and Internet Daily
Goldman Sachs · Jun 9, 2026
US Market Intelligence Morning Briefing
J.P. Morgan · Jun 9, 2026
Harmony Biosciences Key Takeaways 47th Annual Global Healthcare Conference
Goldman Sachs · Jun 9, 2026
Research Unplugged: GS Media & Internet Initiations
Goldman Sachs · Jun 9, 2026
Hemab Therapeutics Holdings Strategic Interests and Market Opportunity in VWD
Goldman Sachs · Jun 9, 2026
Sino Biopharmaceutical Key Takeaways
Goldman Sachs · Jun 9, 2026
Nordic Alert
SEB · Jun 9, 2026
Global Macro Monthly
TS Lombard · Jun 9, 2026
Goal Kickstart
Goldman Sachs · Jun 9, 2026
Research Unplugged Goal Asset Allocation Webinar
Goldman Sachs · Jun 9, 2026
Rhythm Pharmaceuticals Key Takeaways
Goldman Sachs · Jun 9, 2026
Europe First to Market
J.P. Morgan · Jun 9, 2026
GS Japan 30 Years in the Making
Goldman Sachs · Jun 9, 2026
JPY Household Investment In Overseas Assets And Implications For The JPY
Barclays · Jun 9, 2026
Barclays Equity Factor Insights
Barclays · Jun 9, 2026
FX Daily
Crédit Agricole Corporate and Investment Bank · Jun 9, 2026
Japan BOP Update
Goldman Sachs · Jun 8, 2026
GS TMT Spec Sales
Goldman Sachs · Jun 8, 2026
US Biopharmaceuticals: Is It Time To Reassess Biopharma
Bank of America · Jun 8, 2026
Trading Catalysts
Bank of America · Jun 8, 2026